• Cynata Therapeutics requests voluntary suspension of its securities
• Suspension pending the release of Phase 3 OA Trial and Phase 2 GvHD Trial results
• Expected announcement date for trial results is June 20, 2026

Cynata Therapeutics Limited (ASX: CYP) has requested a voluntary suspension of its securities from quotation under Listing Rule 17.2, pending the release of results from two significant clinical trials: the Phase 3 Osteoarthritis Trial (OA Trial) and the Phase 2 Graft versus Host Disease Trial (GvHD Trial). The suspension will remain in effect until the earlier of the announcement of the trial results or the commencement of trading on Friday, June 19, 2026. Cynata expects to announce the results of these trials on or before Friday, June 20, 2026. The company is not aware of any reason why the voluntary suspension should not be granted and does not have any other information necessary to inform the market about the suspension.

Cynata Therapeutics anticipates releasing the results of its Phase 3 OA Trial and Phase 2 GvHD Trial by June 20, 2026, which will provide further insights into the efficacy and safety of its therapeutic stem cell platform technology.